ATLANTA, GA — June 16, 2025 — Atlanta Biomedical Ventures, a clinical-stage medical technology company focused on next-generation diagnostic solutions, today announced the close of a $28 million Series B funding round. The round was led by MedTech Growth Partners, with participation from existing investors Southeastern Health Capital and BioForward Ventures. The company plans to deploy the new capital toward advancing its flagship platform, the ABV-400 Rapid Biomarker System, through late-stage clinical trials and toward expanding its commercial infrastructure ahead of an anticipated 2026 product launch. The ABV-400 is designed to deliver hospital-grade diagnostic accuracy at the point of care, reducing patient wait times by up to 70% compared to traditional laboratory testing methods. "This funding represents a significant vote of confidence in both our technology and our team," said Dr. Sandra Merritt, founder and chief executive officer of Atlanta Biomedical Ventures. "We are entering a critical phase of development, and this capital positions us to bring a genuinely transformative diagnostic tool to clinicians and patients who need faster, more reliable answers." The company also announced plans to grow its Atlanta-based workforce by approximately 40 employees over the next 18 months, adding roles in clinical affairs, regulatory strategy, and sales operations. Atlanta Biomedical Ventures has now raised $47 million in total funding since its founding in 2019. **About Atlanta Biomedical Ventures:** Atlanta Biomedical Ventures is a clinical-stage medical technology company developing rapid diagnostic platforms designed to improve patient outcomes and reduce healthcare costs. Headquartered in Atlanta, GA, the company partners with hospitals, health systems, and research institutions nationwide. For more information, visit www.atlantabiomedicalventures.com. ---